Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2011

View Archived Issues

AMG-386 does not improve efficacy of CX combination in gastroesophageal adenocarcinoma

BI-2536 shows potential in models of osteosarcoma

Escitalopram is safe and reduces menopausal hot flashes

Phase I trial assesses temsirolimus/sorafenib combination in HCC

Genome analyses identify distinct loci for CAD and for myocardial infarction in CAD

Kyowa Hakko Kirin and Amgen collaborate on AMG-827

FDA refuses to file Gilead's Truvada/TMC-278 NDA for HIV-1

Serum level of angiogenin-directed IgM antibodies as a biomarker of response to osteosarcoma therapy

New sodium channel blockers presented

New protein kinase inhibitors described by sanofi-aventis

New inhibitors of serine/threonine-protein kinase mTOR claimed

ASSERT trial data suggest potential of RVX-208 in Alzheimer's disease

FDA clears clinical testing of AREVA's alpha radioimmunotherapy involving 212Pb

ChemoCentryx begins phase I trial of CCX-832 under alliance with GSK

Sunshine Biopharma and Binghamton University sign agreement for Adva-27a

New inhibitors discovered of PI3K-alpha/mTOR/TNF-alpha/IL-6

NIH funds AndroScience's development of AR degradation enhancer for SBMA

E.U. orphan drug status recommended for ALN-TTR01 in familial amyloidotic polyneuropathy

Enrollment begins in phase IIb RX-10100 trial in major depressive disorder

Chugai Pharma files for new indication of Pegasys

MBL-HCV1 enters phase II trial to prevent HCV reinfection in liver transplant recipients

GSK receives FDA complete response letter regarding Avodart sNDA

Anadys begins dosing in phase IIb ANA-598 trial in hepatitis C

AB Science initiates phase III masitinib study in severe asthma

Ligand Pharma acquires CyDex Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...